4月15日，据CDE官网消息，信达生物制药（苏州）有限公司联合申请药品“IBI133”，获得临床试验默示许可，受理号CXSL2400085。
公示信息显示，药品“IBI133”适应症：不可切除的局部晚期或转移性实体瘤。
信达生物制药（苏州）有限公司药品申请临床试验默示许可获受理
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.